The EPS projection of Array BioPharma Inc. (NASDAQ:ARRY) for period quarter closed 2016-12-31 is $-0.21.
The EPS estimates given 30-days and 1 week ago were $-0.21 and $-0.21, correspondingly. This number 90 and 60 days before was $-0.21 and $-0.21 respectively. Yet, from last week, the change in EPS prediction is 0%.
For the quarter ended 4 mean estimate is $-0.21 based on 6 EPS estimations. As on 2016-08-04 estimated EPS was $-0.17 showing surprise of $-0.02, or -13.33%. Following the given predictions, the standard deviation is $0.13.
The upgrade count for EPS revisions was 0 a week earlier paralleled to negative revisions of 0. In last 60-days and 1- month, the upgrade in EPS reviews were 1 and 1 correspondingly, though for a quarter and 120-days ago, it was 0 and 0 in that sequence.
The negative reviews of EPS in the last 60-days and 1-month were 0 and 0 in that order. But, a quarter and 120-days ago, this numeral was 1 and 1 correspondingly.
EPS reviews downgrade and upgrade for last 18 days were 0 and 0, correspondingly.
Quarterly Sales Estimates
The mathematical mean of apparent yearly sales of Array BioPharma Inc. (NASDAQ:ARRY) is $40.82 and the median is $43.15. The estimate is stated by 3 analysts for the fiscal 2017.
The highest yearly projection is $58.71 and lowest sales mark is $20.6. This results a standard deviation of $19.161.
Almost 3 have reviewed sales target for better in the past week and 3 have downgraded forecasts. Subject to the stated estimates, the intended change in disclosed target from the past week is 0%.
Nearly 3 revised sales predictions for better over the past month and 3 have downgraded forecasts. It suggests an average deviation of -27.521% across given estimates.
Just about 3 have revised sales forecast up over the quarter and 3 have downgraded forecasts, hinting to a deviation of 69.237%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...